DelveInsight’s “Turner Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Turner Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Turner Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Turner Syndrome treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Turner Syndrome: An Overview
Turner syndrome is a rare chromosomal disorder that affects females only. Turner syndrome is highly variable and can differ dramatically from one person to another. Many features of this disorder are nonspecific, and others may develop slowly over time or can be subtle.
Almost all females with Turner syndrome exhibit growth failure and attain a final height that is shorter than average (short stature). Another common feature of Turner syndrome is the failure of the ovaries to develop properly (gonadal dysgenesis). Affected females may develop learning disabilities, especially difficulties with visual-spatial relationships. Many physical abnormalities occur in this condition, such as down-turning eyelids, low-set, prominent ears, neck webbing, etc.
The affected individual may have distinctive heart, liver, and kidney abnormalities. Most cases of Turner syndrome are not inherited. When this condition results from monosomy X, the chromosomal abnormality occurs as a random event during the formation of reproductive cells in the affected person’s parent. The current treatment market includes human growth hormone therapy, estrogen replacement therapy, progesterone replacement therapy, psychological therapy, and others.
Turner Syndrome Market Key Facts
According to the National Organization for Rare Disorders, Turner Syndrome affects approximately 1 in 2,000‒2,500 live female births.
As per the National Health Service, 1 in every 1,800 girls has Turner Syndrome in the UK.
According to the National Health Service, in about half of the cases of Turner Syndrome, one X chromosome is missing or abnormal, but not in all cells of the body. This is referred to as “Mosaic Turner Syndrome.”
According to the article by Nielsen et al., Turner Syndrome occurs in approximately 1 in 1,893 live female births, based on epidemiological and newborn genetic screening data.
One-third to one-half of individuals with Turner syndrome are born with a heart defect.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Turner Syndrome pipeline therapies. It also thoroughly assesses the Turner Syndrome market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Turner Syndrome drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Turner Syndrome Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Turner Syndrome epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Turner Syndrome epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Turner Syndrome Epidemiology, Segmented as –
Total Prevalent Population of Turner Syndrome in the 7MM (2019–2032)
Type-specific Prevalent Cases of Turner Syndrome in the 7MM (2019–2032)
Diagnosed and Treatable Cases of Turner Syndrome in the 7MM (2019–2032)
Turner Syndrome Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Turner Syndrome market or expected to be launched during the study period. The analysis covers the Turner Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Turner Syndrome drugs based on their sale and market share.
The report also covers the Turner Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Turner Syndrome companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Turner Syndrome Market Will Evolve and Grow by 2032 @
Turner Syndrome Therapeutics Analysis
Currently, no cure is available for Turner syndrome, but many of the associated symptoms can be treated. The treatment options include growth-promoting therapies and hormone replacement therapies, such as estrogen and progestin replacement therapy.
The goal of growth-promoting therapies is to make the patient reach a height that lessens physical limitations and allows puberty to begin at an age similar to that of her peers. The essential component of growth-promoting therapy is growth hormone (GH), which increases development velocity and results in a modest increase in adult height. Most girls will require female hormone replacement (estrogen and progestin) to initiate and/or complete the puberty process while receiving GH therapy. The way estrogen is taken, its dosage, and the speed at which the dose is increased will affect the growth and adult height.
The US FDA drugs approved drugs for Turner syndrome is Somatropin (r-DNA) for injection—brand names Humatrope and Nutropin AQ. To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Turner Syndrome. Currently, Lumos Pharma is leading the therapeutics market with its Turner Syndrome drug candidates in the most advanced stage of clinical development.
Turner Syndrome Companies Actively Working in the Therapeutics Market Include
And Many Others
Emerging and Marketed Turner Syndrome Therapies Covered in the Report Include:
LUM 201: Lumos Pharma
LUM-201/Ibutamoren, which is under development by Lumos Pharma for the treatment of Turner syndrome, pediatric growth hormone deficiency, and children born small for gestational age. LUM201 is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland. The molecule acts as an agonist of the GH secretagogue receptor to stimulate GH release.
The current clinical pipeline of Turner syndrome is very narrow, as most of the companies are focusing only on the biosimilar of Somatropin (r-DNA) for injection Patients with Turner syndrome have to cope with many difficulties; they need not only life-long medical surveillance but also psychological care and treatment for a good outcome.
There are lots of opportunities for pharmaceutical companies to develop novel therapies for the treatment of Turner Syndrome due to limited therapeutic options available in the market.
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Turner Syndrome Competitive Intelligence Analysis
4. Turner Syndrome Market Overview at a Glance
5. Turner Syndrome Disease Background and Overview
6. Turner Syndrome Patient Journey
7. Turner Syndrome Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Turner Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Turner Syndrome Unmet Needs
10. Key Endpoints of Turner Syndrome Treatment
11. Turner Syndrome Marketed Therapies
12. Turner Syndrome Emerging Drugs and Latest Therapeutic Advances
13. Turner Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Turner Syndrome Market Outlook (In US, EU5, and Japan)
16. Turner Syndrome Companies Active in the Market
17. Turner Syndrome Access and Reimbursement Overview
18. KOL Views on the Turner Syndrome Market
19. Turner Syndrome Market Drivers
20. Turner Syndrome Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Substance Use Disorder Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Substance Use Disorder market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Substance Use Disorder market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States